Dipna Pharmachem Ltd
Incorporated in 2011, Dipna Pharmachem Ltd
is in the business of Pharmaceutical Trading[1]
- Market Cap ₹ 36.4 Cr.
- Current Price ₹ 13.8
- High / Low ₹ 26.3 / 7.10
- Stock P/E 17.7
- Book Value ₹ 24.5
- Dividend Yield 0.00 %
- ROCE 6.64 %
- ROE 2.55 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.56 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -0.85%
- Promoter holding is low: 9.13%
- Company has a low return on equity of 3.62% over last 3 years.
- Debtor days have increased from 103 to 135 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 108 | |
| 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 103 | |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% | 5% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 3 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | |
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 | 0.86 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 20% |
| TTM: | -40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | -6% |
| TTM: | 147% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| 1 Year: | 82% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 24 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 35 |
| 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 14 | |
| 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 105 | |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 | |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
Cash Flows
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| -3 | -2 | 3 | -21 | -5 | -9 | |||
| 0 | 0 | -0 | -0 | -0 | -0 | |||
| 3 | 2 | -3 | 26 | 14 | -4 | |||
| Net Cash Flow | 0 | 0 | -0 | 5 | 8 | -13 |
Ratios
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment
29 Nov - Allotment of 22,44,000 shares at Rs13.05; Rs2.1963 crore received; post-issue shares 2,62,89,250
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today, I.E., Saturday, 29Th November, 2025
29 Nov - Allotment of 22,44,000 shares on 29-Nov-2025; Rs.2.1963 crore received; post-issue 8.54% holding.
-
Statement Of Deviation And Variation
26 Nov - Unaudited H1 results to 30-Sep-2025; rights issue Rs11.84 crore; preferential warrants receipts Rs18.93 crore.
-
Integrated Filing (Financial) For The Half Year Ended On 30Th September, 2025
26 Nov - Unaudited H1 results (30-09-2025): Total income Rs7,354.12 lakh; PAT Rs141.10 lakh; warrants proceeds ~Rs18.92 crore.
- Unaudited Financial Results For The Half Year Ended On 30Th September, 2025. 26 Nov
Business Overview:[1]
DPL is a trader, importer, and exporter of industrial Chemical and Pharmaceutical Raw materials, APIs, Solvents, Excipients, Intermediates, and Formulations. It provides assistance in setting up contract manufacturing compliance for regulated, semi-regulated pharmaceutical companies with all the global benchmark parameters of certificates like WHO-GMP